Weekly Digest – February 2026 Weekly Digest – February 2026 03 February 2026: Datroway granted priority review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Datroway has taken a […]
Weekly Digest – February 2026 Weekly Digest – February 2026 30 January 2026: Takeda submits new drug application for Mirvetuximab Soravtansine for folate receptor alpha-positive, platinum-resistant recurrent ovarian cancer in Japan Takeda has moved a step closer to expanding treatment […]
Weekly Digest – February 2026 Weekly Digest – February 2026 30 January 2026: Astellas submits Supplemental New Drug Application in Japan for PADCEV™ (Enfortumab vedotin) with Keytruda ® (Pembrolizumab) for certain patients with muscle-invasive bladder cancer Astellas Pharma has advanced […]
Weekly Digest – February 2026 Weekly Digest – February 2026 04 February 2026: The supplemental application for BB-1701 for injection from Bliss Biopharmaceuticals (Hangzhou) has been accepted by NMPA The latest update from China’s drug regulatory system shows progress in […]
Weekly Digest – February 2026 Weekly Digest – February 2026 04 February 2026: DS3790 enters clinical development as first DXd ADC in hematology from industry-leading ADC portfolio of Daiichi Sankyo Daiichi Sankyo has reached a key milestone in hematologic oncology, […]
Weekly Digest – February 2026 Weekly Digest – February 2026 02 February 2026: AdvanCell announces collaboration and exclusive licensing agreement with 48Hour discovery to develop a novel peptide-based lead-212 radiotherapeutic for a gastrointestinal cancer with significant medical need AdvanCell has […]
Weekly Digest – January 2026 Weekly Digest – January 2026 27 January 2026: Henlius receives an IND approval for Its PD-L1-targeting ADC HLX43 in combination with anti-PD-1 mAb Serplulimab and novel anti-EGFR mAb HLX07 Shanghai Henlius Biotech has secured regulatory […]
Weekly Digest – January 2026 Weekly Digest – January 2026 29 January 2026: MT-2111 (loncastuximab tesirine-lpyl) achieved primary endpoint in phase 2 part of Japanese phase 1/2 study for relapsed or refractory Diffuse Large B-cell Lymphoma Tanabe Pharma announced a […]
Weekly Digest – January 2026 Weekly Digest – January 2026 22 January 2026: China Isotope & Radiation Corporation signs commercial deal for Pluvicto, China’s first PSMA radioligand therapy China Isotope & Radiation Corporation disclosed that its subsidiary, Atom High-Tech, has […]
Weekly Digest – January 2026 Weekly Digest – January 2026 26 January 2026: HealZen announces global strategic collaboration to Develop degrader-antibody conjugate therapeutics HealZen Therapeutics has taken a major step onto the global stage, announcing a strategic collaboration with a […]
